ICON Public (NASDAQ:ICLR) Reaches New 52-Week Low – Here’s What Happened

ICON Public Limited (NASDAQ:ICLR) shares hit a new 52-week low on Friday . The company traded as low as $219.81 and last traded at $220.41, with a volume of 1098276 shares changing hands. The stock had previously closed at $222.11.

Analysts Set New Price Targets

Several research firms have issued reports on ICLR. StockNews.com cut ICON Public from a “buy” rating to a “hold” rating in a research report on Thursday, September 19th. The Goldman Sachs Group cut their price objective on ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Robert W. Baird downgraded ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 target price for the company. in a report on Thursday, October 24th. Redburn Atlantic began coverage on shares of ICON Public in a research note on Monday, October 14th. They set a “neutral” rating and a $311.00 price target on the stock. Finally, Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $304.27.

ICON Public Trading Down 0.8 %

The stock has a market cap of $18.18 billion, a price-to-earnings ratio of 24.57, a PEG ratio of 1.64 and a beta of 1.25. The business has a fifty day simple moving average of $288.08 and a 200 day simple moving average of $307.38. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The company had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.10 EPS. As a group, equities analysts anticipate that ICON Public Limited will post 13.43 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ICLR. EverSource Wealth Advisors LLC grew its position in shares of ICON Public by 17.4% in the first quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after purchasing an additional 42 shares during the period. Motco grew its holdings in ICON Public by 1.5% in the 1st quarter. Motco now owns 3,882 shares of the medical research company’s stock valued at $1,304,000 after buying an additional 59 shares during the period. First National Bank of Hutchinson increased its stake in shares of ICON Public by 5.7% during the 1st quarter. First National Bank of Hutchinson now owns 1,135 shares of the medical research company’s stock valued at $381,000 after acquiring an additional 61 shares during the last quarter. Arkadios Wealth Advisors lifted its holdings in shares of ICON Public by 5.0% during the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock worth $371,000 after acquiring an additional 62 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of ICON Public by 50.0% in the second quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock worth $82,000 after acquiring an additional 87 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.